United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol-Myers

Moderna

Bristol Myers Squibb is trading at a significant discount. Moderna has a lot of irons in the fire.

3 Surprisingly Underrated Stocks to Buy Right Now

AdvanSix

IAMGOLD

Pilgrim's Pride

Unlock your portfolio value by investing in these high-earnings stocks like PPC, PFE, IAG and ASIX.

4 High Earnings Yield Stocks That Value Investors Should Buy Now

Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. The oncology business shows promising growth, particularly with products like Xtandi and Lobrena, supporting Pfizer's long-term potential. Pfizer's guidance for FY 2024 EPS has been raised, indicating strong earnings potential and undervaluation by the market.

Pfizer: A 6% Yielding Value Deal

Carnival

Teledyne Technologies

Zoetis

Four S&P 500 laggards of this year have double-digit upside left for the rest of 2024. These are: CCL, PFE, ZTS, TDY.

Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside

Pfizer (PFE) closed the most recent trading day at $28.97, moving +0.14% from the previous trading session.

Pfizer (PFE) Rises But Trails Market: What Investors Should Know

The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta.

FDA alerts patients about Pfizer's Oxbryta withdrawal

PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.

Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer (PFE) shares declined Thursday after the drug maker recalled all lots of its sickle cell disease medicine worldwide because of concerns it could lead to severe pain and possibly death in patients.

Pfizer Recalls All of Its Sickle Cell Disease Treatment Over Safety Concerns

The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on Thursday.

EU regulator recommends suspension of Pfizer's sickle cell disease treatment

AstraZeneca

Bayer AG

Eli Lilly

Sanofi

Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.

Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.

Pfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years?

Can Pfizer Stock Rise 2x To $60?

Verizon

Verizon and Pfizer offer attractive dividend yields above 5%, supported by strong market positions. Both companies face challenges but have strategies in place to maintain their generous payouts.

2 High-Yield Dividend Stocks That Can Deliver a Lifetime of Passive Income

Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the world's poorest nations at not-for-profit prices, just over two years after it launched.

Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO

W. P. Carey

W.P. Carey reduced its dividend after spinning off its office properties last year but still offers an ultra-high yield. Pfizer's been raising its dividend every year since 2009, and an unprecedented number of recently launched drugs could help it rise much further.

3 Ultra-High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved patient population.

Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Global Markets

The benefits of Oxbryta no longer outweigh the risks, Pfizer says.

Pfizer yanks sickle-cell treatment worldwide after possible link to deaths

U.S. drugmaker Pfizer said on Wednesday it would voluntarily withdraw its therapy Oxbryta, used for the treatment of sickle cell disease, in all markets where it is approved.

Pfizer withdraws sickle cell disease treatment from all markets

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickl.

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer is now working on a new approach to weight, helping some patients gain weight. Is Pfizer stock a buy or a sell?

Is Pfizer Stock A Buy Or A Sell On Its New Weight-Gain Approach?

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal.

Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK

Citigroup

Comcast

Altria

Exxon Mobil

24/7 Wall St. Insights The futures market has priced in a 100% chance of a September rate cut.

5 Blue Chip Dividend Giants Passive Income Investors Can Always Count On

Lower interest rates can make dividend stocks such as Pfizer and Verizon more attractive investment options. Falling rates can reduce companies' interest expenses, which can help Carnival better manage its high debt load.

3 Ultra-Cheap Stocks That Could Get a Boost From Fed Rate Cuts

BioNTech SE

The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.

News for Pfizer Stock (PFE)